Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311 - common questions asked - Timothy Heuer Ph.D. - twoXAR Pharmaceuticals @twoX...

Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311 - common questions asked - Timothy Heuer Ph.D. - twoXAR Pharmaceuticals @twoX...

User Photo
Cancer-News

1 month
12 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Timothy Heuer, Ph.D., twoXAR Pharmaceuticals discusses Presents Positive Preclinical Safety & Efficacy Data for its Novel Investigational Cancer Treatment TXR-311

AACR2020

https://www.prnewswire.com/news-releases/twoxar-pharmaceuticals-presents-positive-preclinical-safety-and-efficacy-data-for-its-novel-investigational-cancer-treatment-txr-311-301080554.html
Up Next Autoplay